The Impact Of Rituxan For The Treatment Of Follicular Lymphoma

The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New analysis provides more statement that treating certain lymphoma patients with an extravagant drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly further life span, raising questions about whether it's worth taking. People with lymphoma who are making allowance for maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, guide of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago ipca keraglo men benefits. The exploration involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a word that refers to cancers of the immune system.

Though it can be fatal, most males and females live for at least 10 years after diagnosis. There has been debate over whether people with the disease should drink Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical train that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not tablet. All formerly had taken the drug right after receiving chemotherapy.

In the next three years, the inquiry found, people taking the drug took longer, on average, to evolve symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't undergo the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.

The analgesic "should now be considered as first-line healing for these patients," wrote Dr Gilles Salles of Hospices Civils de Lyon & Universite Claude Bernard in Lyon, France, and his investigate colleagues. But Rosen said there's still a rank over use of the drug as maintenance therapy. "Physicians are falling into two groups. One says, 'There was no survival advantage, I'd just stop until you have flow and then retreat you.

That's not unreasonable'". Another group "would say that there's potentially better superiority of life during the period without disease. But the psychological benefits from not having any evidence of c murrain are hard to measure".

In a comment accompanying the report in The Lancet, Dr Jonathan Friedberg, of the hematology and oncology boundary at the University of Rochester in Rochester, NY, wrote that "an enquiry of cost-effectiveness would be very helpful. In an era of increased health-care costs, what benefit is necessary to defend the cost of this maintenance strategy, which at my institution would cost Medicare more than $60000 per patient?" Friedberg asked.

He also described as unripe the researchers' statement that maintenance therapy with the drug should be prescribed for all mortals with follicular lymphoma who are initially treated with rituximab plus chemotherapy natural. "However, maintenance is an option," Friedberg said, adding that "the investigators are to be congratulated for this outstanding contribution and are strongly encouraged to carry on follow-up of these patients to answer the questions that remain".